Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. The Company has established a robust genome editing platform based on CRISPR/Cas9 technology, which includes foundational intellectual property, advanced capabilities in engineering and delivery, and a full-spectrum of R&D expertise. Editas Medicine is advancing a pipeline of genome editing medicines for a range of diseases, including: genetic blindness, sickle cell disease, beta-thalassemia, cancer, and more. The Company is headquartered in Cambridge, Massachusetts.